Showing results for:

  Hoag Memorial Hospital Presbyterian announced today the addition of Flynn Andrizzi, Ph.D., as the senior vice president and executive director of Hoag Hospital Foundation. Dr. Andrizzi was selected following an extensive national search process from a pool of highly qualified candidates.   Dr. Andrizzi joins Hoag with over 20 years of experience in fundraising … Read More

Tuesday, May 18, 2010 Hoag Health Center – Huntington Beach Celebrates 20 years in “Surf City”​ Huntington Beach, Calif. – Demonstrating its legacy of providing the highest quality health care services to the residents of Huntington Beach, Hoag Memorial Hospital Presbyterian is celebrating the 20th anniversary of the groundbreaking of Hoag Health Center – Huntington … Read More

Demonstrating its legacy of providing quality health care services to the residents of Huntington Beach, Hoag Memorial Hospital Presbyterian is celebrating the 20th anniversary of the groundbreaking Hoag Health Center Huntington Beach.   “We have always been a part of this community and we’re grateful to the City of Huntington Beach for being our partner … Read More

Monday, February 1, 2010 Hoag Hospital Focuses February’s Heart Month on Heart Valve Disease​​ Newport Beach, Calif. – This February, Hoag Hospital is participating in national Heart Awareness Month, with a focus on heart valve disease. While heart valve disease cannot be prevented, it can be detected and treated early. According to the American Heart … Read More

Sunday, March 01, 2009 Study Shows Patient-Specific Cancer Immune Cell Therapy for Brain Tumors Promising as Adjunctive Therapy Newport Beach, Calif. – Hoag Hospital announced encouraging clinical study results for the instillation of a patient-specific cancer immune cell therapy as an adjunctive treatment for glioblastoma multiforme (GBM). The non-randomized, phase 2 study concluded that intralesional … Read More

Sunday, March 01, 2009 Newport Beach, Calif. – Hoag Hospital announced encouraging clinical study results for the instillation of a patient-specific cancer immune cell therapy as an adjunctive treatment for glioblastoma multiforme (GBM). The non-randomized, phase 2 study concluded that intralesional therapy with autologous lymphokine-activated killer (LAK) cells is safe and the survival sufficiently encouraging … Read More